Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.

Sci Rep · 2018 · PMC6048117 · PMID 30013201

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

trend toward significancep = 0.067so close (0.05 < p ≤ 0.1)

We also found a marginal correlation trend toward significance between rotational behavior on day 45 and normalized striatal TH-IR in animals receiving post Exendin −4 treatment (p = 0.067, R = 0.429, data not shown).

also in 304 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.